KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Depreciation Expense (2022 - 2023)

AbCellera Biologics' Depreciation Expense history spans 2 years, with the latest figure at $3.9 million for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation Expense rose 40.75% year-over-year to $3.9 million, compared with a TTM value of $12.9 million through Dec 2023, up 43.81%, and an annual FY2024 reading of $12.5 million, down 1.73% over the prior year.
  • Depreciation Expense for Q4 2023 was $3.9 million at AbCellera Biologics, up from $3.1 million in the prior quarter.
  • The five-year high for Depreciation Expense was $3.9 million in Q4 2023, with the low at $1.4 million in Q1 2022.